Pharmacological inhibition of RAS pathway alleviates spine deformity in a mouse model of neurofibromatosis type 1

Abstract

Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 in 3 000 people due to heterozygous mutations in the NF1 gene. Patients with NF1 can develop multiple symptoms, such as neurofibromas, skin hyperpigmentation, and bone abnormalities, including tibial pseudarthrosis and spine deformity. Here, we aimed to elucidate the cellular origin and pathogenic mechanism of NF1 spine deformity. We explored the Prss56-Nf1 knockout (KO) mouse model that recapitulates neurofibromas and pseudarthrosis by carrying Nf1 gene inactivation in Prss56-expressing boundary cap cells, a neural crest subset, and their derivatives. Micro-CT analyses showed that Prss56-Nf1 KO mice exhibit spine deformity from 12 months of age, associated with vertebral anomalies reminiscent of patients with NF1. Fate mapping revealed a significant increase in OSX⁺ osteoblasts of the Prss56 lineage in vertebrae of Prss56-Nf1 KO mice. Increased traced Nf1-deficient cells correlated with increased vertebral bone volume and kyphosis spine curvature. Finally, we showed that treating Prss56-Nf1 KO mice with RAS-MAPK pathway inhibitors prevented spine deformity. Overall, the Prss56-Nf1 KO mouse model unravels the role of osteoblasts from the Prss56 lineage as the cellular origin of NF1 spine deformity and highlights RAS-MAPK pathway inhibition as a promising therapeutic strategy for preventing NF1 spine deformity.

References

[1] Boachie-Adjei O, Lonner B. Spinal deformity. Pediatr. Clin. North Am., 1996, 43: 883-897.

[2] Smith JS, et al. . Prevalence and type of cervical deformity among 470 adults with thoracolumbar deformity. Spine, 2014, 39: E1001-E1009.

[3] Sucato DJ. Management of severe spinal deformity: scoliosis and kyphosis. Spine, 2010, 35: 2186-2192.

[4] Mo F, Cunningham ME. Pediatric scoliosis. Curr. Rev. Musculoskelet. Med, 2011, 4: 175-182.

[5] Dickson R. The aetiology of spinal deformities. Lancet, 1988, 331: 1151-1155.

[6] Burwell RG. Aetiology of idiopathic scoliosis: current concepts. Pediatr. Rehabil., 2003, 6: 137-170.

[7] Konieczny MR, Senyurt H, Krauspe R. Epidemiology of adolescent idiopathic scoliosis. J. Child.’s. Orthop., 2013, 7: 3-9.

[8] Weinstein SL. Adolescent idiopathic scoliosis: prevalence and natural history. Instr. Course Lect., 1989, 38: 115-128. DOI:

[9] Asher MA, Burton DC. Adolescent idiopathic scoliosis: natural history and long term treatment effects. Scoliosis, 2006, 1: 2

[10] Toro G, et al. . Natural history of scoliosis in children with NF1: an observation study. Healthcare, 2021, 9: 881

[11] Well L, et al. . Phenotyping spinal abnormalities in patients with Neurofibromatosis type 1 using whole-body MRI. Sci. Rep., 2021, 1116889

[12] Tsirikos AI, Saifuddin A, Noordeen MH. Spinal deformity in neurofibromatosis type-1: diagnosis and treatment. Eur. Spine J., 2005, 14: 427-439.

[13] Friedman, J. M. Neurofibromatosis 1. in GeneReviews® (eds Adam, M. P. et al.) (University of Washington, 1993).

[14] McKeever K, Shepherd CW, Crawford H, Morrison PJ. An epidemiological, clinical and genetic survey of neurofibromatosis type 1 in children under sixteen years of age. Ulst. Med. J., 2008, 77: 160-163

[15] Uusitalo E, et al. . Incidence and mortality of neurofibromatosis: a total population study in Finland. J. Invest. Dermatol., 2015, 135: 904-906.

[16] Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc. Natl. Acad. Sci. USA, 1991, 88: 9658-9662.

[17] Legius E, et al. . Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet. Med., 2021, 23: 1506-1513.

[18] Elefteriou F, et al. . Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am. J. Med. Genet. Pt A, 2009, 149A: 2327-2338.

[19] Haider S, Le LQ, Cho G, Xi Y, Chhabra A. Scoliosis in neurofibromatosis type 1 on whole-body magnetic resonance imaging: frequency and association with intraspinal and paraspinal tumors. J. Comput. Assist Tomogr., 2022, 46: 231-235.

[20] Durrani AA, Crawford AH, Chouhdry SN, Saifuddin A, Morley TR. Modulation of spinal deformities in patients with neurofibromatosis type 1. Spine, 2000, 25: 69

[21] Vitale MG, Guha A, Skaggs DL. Orthopaedic manifestations of neurofibromatosis in children: an update. Clin. Orthop. Relat. Res., 2002, 401: 107-118.

[22] Rhodes SD, et al. . Dystrophic spinal deformities in a neurofibromatosis type 1 murine model. PLoS One, 2015, 10: e0119093

[23] Sartoris DJ, Jones H. Case report 343. Skelet. Radio., 1986, 15: 60-64.

[24] Beert E, et al. . Biallelic inactivation of NF1 in a sporadic plexiform neurofibroma. Genes Chromosomes Cancer, 2012, 51: 852-857.

[25] Eisenbarth I, Assum G, Kaufmann D, Krone W. Evidence for the presence of the second allele of the neurofibromatosis type 1 gene in melanocytes derived from Café au Lait Macules of NF1 patients. Biochem. Biophys. Res. Commun., 1997, 237: 138-141.

[26] Kluwe L, Friedrich R, Mautner V-F. Loss ofNF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosom. Cancer, 1999, 24: 283-285.

[27] Perrin S, et al. . MEK-SHP2 inhibition prevents tibial pseudarthrosis caused by NF1 loss in Schwann cells and skeletal stem/progenitor cells. Sci. Transl. Med., 2024, 16eadj1597

[28] Margraf RL, et al. . NF1 somatic mutation in dystrophic scoliosis. J. Mol. Neurosci., 2019, 68: 11-18.

[29] Nguyen R, Dombi E, Akshintala S, Baldwin A, Widemann BC. Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. J. Neurooncol., 2015, 121: 209-215.

[30] Elefteriou F, et al. . ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab., 2006, 4: 441-451.

[31] Wang W, et al. . Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum. Mol. Genet., 2011, 20: 3910-3924.

[32] Zhang W, et al. . Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone, 2011, 48: 1378-1387.

[33] Radomska KJ, et al. . Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov., 2019, 9: 130-147.

[34] Gresset A, et al. . Boundary caps give rise to neurogenic stem cells and terminal glia in the skin. Stem Cell Rep., 2015, 5: 278-290.

[35] Radomska KJ, Topilko P. Boundary cap cells in development and disease. Curr. Opin. Neurobiol., 2017, 47: 209-215.

[36] Coulpier F, et al. . Topical delivery of mitogen-activated protein kinase inhibitor binimetinib prevents the development of cutaneous neurofibromas in Neurofibromatosis type 1 mutant mice. Transl. Res., 2023, 261: 16-27.

[37] Gross AM, et al. . Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol., 2023, 25: 1883-1894.

[38] Dombi E, et al. . Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med., 2016, 375: 2550-2560.

[39] Casey D, et al. . FDA approval summary: selumetinib for plexiform neurofibroma. Clin. Cancer Res, 2021, 27: 4142-4146.

[40] de la Croix Ndong J, et al. . Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx^−/− mice. J. Bone Miner. Res., 2015, 30: 55-63.

[41] Sharma R, et al. . Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum. Mol. Genet., 2013, 22: 4818-4828.

[42] Ramachandran M, Tsirikos AI, Lee J, Saifuddin A. Whole-spine magnetic resonance imaging in patients with neurofibromatosis type 1 and spinal deformity. J. Spinal Disord. Tech., 2004, 17: 483-491.

[43] Nichols RJ, et al. . RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol., 2018, 20: 1064-1073.

[44] Xie M, et al. . Schwann cell precursors contribute to skeletal formation during embryonic development in mice and zebrafish. Proc. Natl. Acad. Sci. USA, 2019, 116: 15068-15073.

[45] Madisen L, et al. . A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci., 2010, 13: 133-140.

[46] Zhu Y, et al. . Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev., 2001, 15: 859-876.

[47] Cobb, J. R. Outline for the Study of Scoliosis. InInstructional Course Lectures, American Academy of Orthopaedic Surgeons. (eds Arbor, A. & Edwards, J.W.) 261–275 (1948).

[48] Kawamoto, T. & Kawamoto, K. Preparation of Thin Frozen Sections from Nonfixed and Undecalcified Hard Tissues Using Kawamoto’s Film Method (2020). In Skeletal Development and Repair (ed. Hilton, M. J.) vol. 2230, 259–281 (Springer US, 2021).

Funding

Fondation pour la Recherche Médicale (Foundation for Medical Research in France)(PhD fellowship)

University Paris Est Creteil

Agence Nationale de la Recherche (French National Research Agency)(ANR-21-CE18-007-01)

RIGHTS & PERMISSIONS

The Author(s)